Home » Neuroendocrine tumors: new data on pain relief

Neuroendocrine tumors: new data on pain relief

by admin
Neuroendocrine tumors: new data on pain relief

Good news is on the way for patients with gastroenteropancreatic neuroendocrine tumors or acromegaly. Leading them will be the new data that will be presented at the 19th annual conference of the European Neuroendocrine Tumor Society which takes place from 10 to 11 March in Barcelona. In particular, the data relating to the PRESTO 2 and HomeLAN questionnaires will be presented, which have demonstrated the benefits reported by patients during the administration of lanreotide, a long-acting somatostatin analogue, which inhibits the secretion of growth hormone and some hormones secreted by the digestive system. Investigations indicate that injection site pain was reported by few patients, respectively; while the experience of the injection performed in the context of patient support programs (PSP) has reached high levels of satisfaction.

Data on pain at the injection site

Data from PRESTO 2, an online survey that assessed injection site pain in people with gastroenteropancreatic neuroendocrine tumors (GEP-NET) or acromegaly (n = 219 and n = 85), showed that significantly fewer patients who received lanreotide solution for injection reported injection site pain lasting more than two days after the last dose compared to patients on prolonged-release octreotide (OCT) (6% vs 22.8% Furthermore, compared with OCT, fewer patients treated with lanreotide reported that injection site pain negatively impacted daily life (41% vs 60%).

The impact of pain

“The new data from PRESTO 2 – he says Dermot O’Toole, Consultant Gastroenterologist (at St. Vincent, St. James and Trinity College Dublin Hospitals) and Neuroendocrine Tumor Specialist at the ENETS accredited European Center of Excellence at St. Vincent Dublin Hospital – reinforce the importance of the opinion of the patient in understanding the impact of treatment on their well-being. Injection site pain can be a real concern for patients, especially those on long-term treatment regimens, therefore it is interesting to see that significantly fewer patients on lanreotide reported injection site pain than to patients receiving prolonged-release octreotide. These data will help healthcare professionals better understand the impact of pain at the injection site, an important consideration to discuss with patients when choosing treatment. “

See also  Erectile dysfunction, Covid increases the risk of impotence

The HomeLAN survey

Ipsen will also present new data from the HomeLAN survey, which assessed the level of satisfaction with the injection experience in GEP-NET patients included in PSPs. PSPs of lanreotide autogel are aimed at providing care to patients receiving treatment at home, reducing both the need for travel and the current risk of exposure to Covid-19. Furthermore, in the countries where it is approved, after training, in patients on stable dose treatment, it is possible to carry out the administration of lanreotide autogel independently (alone or by a partner). This study evaluated the patients’ opinion regarding the experience with the injection and the impact of home administration. Overall, 95.5% of patients were satisfied with their latest home injection experience by a healthcare provider, and approximately 70% reported that participation in the PSP made them feel “much” or “enough” able to manage their lives properly. Most participants (85%) strongly agree that PSPs meet their clinical needs.

Neuroendocrine tumors

Neuroendocrine tumors, or NETs, ​​are a group of rare cancers that originate from cells of the neuroendocrine system, spread throughout the body. NETs occur in both men and women, generally between the ages of 50 and 60, although they can affect any age group. The three main sites of origin of NETs are the gastrointestinal tract, the pancreas and the lungs. Symptoms are often unclear and difficult to identify, so full diagnosis can take up to 7 years. New diagnoses of NET are estimated to be on the rise. This mainly depends on better knowledge of the pathology and diagnostic tests.

See also  Breast cancer, who are genomic tests for?

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy